These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 15174901)

  • 21. Influence of the CYP2C9 AND CYP2C19 polymorphisms on phenytoin hydroxylation in healthy individuals from south India.
    Rosemary J; Surendiran A; Rajan S; Shashindran CH; Adithan C
    Indian J Med Res; 2006 May; 123(5):665-70. PubMed ID: 16873909
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Paradoxical urinary phenytoin metabolite (S)/(R) ratios in CYP2C19*1/*2 patients.
    Argikar UA; Cloyd JC; Birnbaum AK; Leppik IE; Conway J; Kshirsagar S; Oetting WS; Klein EC; Remmel RP
    Epilepsy Res; 2006 Sep; 71(1):54-63. PubMed ID: 16815679
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment.
    Crettol S; Déglon JJ; Besson J; Croquette-Krokkar M; Gothuey I; Hämmig R; Monnat M; Hüttemann H; Baumann P; Eap CB
    Clin Pharmacol Ther; 2005 Dec; 78(6):593-604. PubMed ID: 16338275
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics.
    Mamiya K; Ieiri I; Shimamoto J; Yukawa E; Imai J; Ninomiya H; Yamada H; Otsubo K; Higuchi S; Tashiro N
    Epilepsia; 1998 Dec; 39(12):1317-23. PubMed ID: 9860067
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rapid detection of the known SNPs of CYP2C9 using oligonucleotide microarray.
    Wen SY; Wang H; Sun OJ; Wang SQ
    World J Gastroenterol; 2003 Jun; 9(6):1342-6. PubMed ID: 12800253
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Warfarin genotyping in a single PCR reaction for microchip electrophoresis.
    Poe BL; Haverstick DM; Landers JP
    Clin Chem; 2012 Apr; 58(4):725-31. PubMed ID: 22317799
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SYBR Green-based real-time PCR assay for detection of VKORC1 and CYP2C9 polymorphisms that modulate warfarin dose requirement.
    Huang SW; Li Q; Zhu SY; Li L; Xiong F; Jia YK; Xu XM
    Clin Chem Lab Med; 2009; 47(1):26-31. PubMed ID: 19117406
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers.
    Kirchheiner J; Bauer S; Meineke I; Rohde W; Prang V; Meisel C; Roots I; Brockmöller J
    Pharmacogenetics; 2002 Mar; 12(2):101-9. PubMed ID: 11875364
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of assay systems for warfarin-related CYP2C9 and VKORC1 genotyping.
    Maurice CB; Barua PK; Simses D; Smith P; Howe JG; Stack G
    Clin Chim Acta; 2010 Jul; 411(13-14):947-54. PubMed ID: 20226775
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Performance of commercial platforms for rapid genotyping of polymorphisms affecting warfarin dose.
    King CR; Porche-Sorbet RM; Gage BF; Ridker PM; Renaud Y; Phillips MS; Eby C
    Am J Clin Pathol; 2008 Jun; 129(6):876-83. PubMed ID: 18480003
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic Polymorphism of Drug-Metabolizing Enzymes CYP2C9 and CYP2C19 in Moroccan Population.
    Afilal D; Basselam MA; Brakez Z; Chouham S; Brehm A; Izaabel EH
    Genet Test Mol Biomarkers; 2017 May; 21(5):298-304. PubMed ID: 28282224
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population.
    Halling J; Petersen MS; Damkier P; Nielsen F; Grandjean P; Weihe P; Lundgren S; Lundblad MS; Brøsen K
    Eur J Clin Pharmacol; 2005 Aug; 61(7):491-7. PubMed ID: 16025294
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes.
    Yamazaki H; Shimada T
    Arch Biochem Biophys; 1997 Oct; 346(1):161-9. PubMed ID: 9328296
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CYP2C9 and CYP2C19 genetic polymorphisms: frequencies in the south Indian population.
    Jose R; Chandrasekaran A; Sam SS; Gerard N; Chanolean S; Abraham BK; Satyanarayanamoorthy K; Peter A; Rajagopal K
    Fundam Clin Pharmacol; 2005 Feb; 19(1):101-5. PubMed ID: 15660966
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rapid single-nucleotide polymorphism detection of cytochrome P450 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genes for the warfarin dose adjustment by the SMart-amplification process version 2.
    Aomori T; Yamamoto K; Oguchi-Katayama A; Kawai Y; Ishidao T; Mitani Y; Kogo Y; Lezhava A; Fujita Y; Obayashi K; Nakamura K; Kohnke H; Wadelius M; Ekström L; Skogastierna C; Rane A; Kurabayashi M; Murakami M; Cizdziel PE; Hayashizaki Y; Horiuchi R
    Clin Chem; 2009 Apr; 55(4):804-12. PubMed ID: 19181737
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels.
    Kerb R; Aynacioglu AS; Brockmöller J; Schlagenhaufer R; Bauer S; Szekeres T; Hamwi A; Fritzer-Szekeres M; Baumgartner C; Ongen HZ; Güzelbey P; Roots I; Brinkmann U
    Pharmacogenomics J; 2001; 1(3):204-10. PubMed ID: 11908757
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Allele and genotype frequencies of the polymorphic cytochrome P450 genes (CYP1A1, CYP3A4, CYP3A5, CYP2C9 and CYP2C19) in the Jordanian population.
    Yousef AM; Bulatova NR; Newman W; Hakooz N; Ismail S; Qusa H; Zahran F; Anwar Ababneh N; Hasan F; Zaloom I; Khayat G; Al-Zmili R; Naffa R; Al-Diab O
    Mol Biol Rep; 2012 Oct; 39(10):9423-33. PubMed ID: 22722998
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic polymorphism of CYP2C9 and CYP2C19 in a Bolivian population: an investigative and comparative study.
    Bravo-Villalta HV; Yamamoto K; Nakamura K; Bayá A; Okada Y; Horiuchi R
    Eur J Clin Pharmacol; 2005 May; 61(3):179-84. PubMed ID: 15776277
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans.
    Shon JH; Yoon YR; Kim KA; Lim YC; Lee KJ; Park JY; Cha IJ; Flockhart DA; Shin JG
    Pharmacogenetics; 2002 Mar; 12(2):111-9. PubMed ID: 11875365
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population.
    Allabi AC; Gala JL; Horsmans Y
    Pharmacogenet Genomics; 2005 Nov; 15(11):779-86. PubMed ID: 16220110
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.